K

Kiora Pharmaceuticals
D

KPRX

3.50000
USD
-0.05
(-1.41%)
مغلق
حجم التداول
438
الربح لكل سهم
0
العائد الربحي
0
P/E
0
حجم السوق
10,396,908
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ARWR
    -1.160
    (-4.06%)
    27.410 USD
    A
    AUPH
    -0.28000
    (-4.76%)
    5.60000 USD
    D
    DVAX
    -0.280
    (-2.50%)
    10.910 USD
    F
    FOLD
    -0.140
    (-1.36%)
    10.180 USD
    I
    INSM
    2.510
    (3.45%)
    75.330 USD
    P
    PTCT
    -1.190
    (-3.51%)
    32.710 USD
    R
    RARE
    -0.870
    (-1.93%)
    44.140 USD
    R
    RETA
    0
    (0%)
    0.000000 USD
    S
    SRPT
    1.650
    (1.16%)
    144.000 USD
    المزيد
الأخبار
المقالات

العنوان: Kiora Pharmaceuticals Inc.

القطاع: Healthcare
الصناعة: Biotechnology
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.